Objective: The aim of this study was to ascertain the experiences, views and monitoring practices of Australian child psychiatrists regarding the metabolic and other side effects of second-generation antipsychotics (SGAs).
Method: A 19-item questionnaire was posted to all members of the RANZCP Faculty of Child and Adolescent Psychiatry living in Australia.
Results: Of the 290 eligible members of the Faculty of Child and Adolescent Psychiatry, 126 (43%) returned a useable survey. SGAs are commonly prescribed for a range of disorders. The majority of respondents expressed a high level of concern regarding weight gain and other metabolic side effects. Weight gain was the most frequently observed and monitored side effect in clinical practice. Other side effects were observed and monitored to a variable extent. Notably, monitoring practices did not parallel psychiatrists’ reported level of concern or knowledge regarding weight gain and metabolic side effects, nor coincide with published recommendations.
Conclusions: Further research is required into the use, efficacy, side effects and monitoring of SGAs in children and adolescents, and there is a need to ensure that monitoring guidelines are implemented in clinical practice. This need is heightened by the likelihood that our data on clinicians’ practice, which is based on their perceptions, may overestimate what actually occurs.
AparasuRRBhataraV. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004. Current Medical Research and Opinion2007; 23: 48–55.
3.
CooperWOArbogastPGDingHHicksonGBFuchsCRayWA. Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatrics2006; 6: 79–83.
4.
CooperWOHicksonGBFuchsCArbogastPGRayWA. New users of antipsychotic medications among children enrolled in TennCare. Archives of Pediatrics and Adolescent Medicine2004; 158: 753–759.
5.
PatelNCSanchezRJJohnsrudMTCrismonML. Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. Journal of Child and Adolescent Psychopharmacology2006; 12: 221–229.
6.
OlfsonMBlancoCLiuLMorenoCLajeG. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry2006; 63: 679–685.
7.
PatelNCCrismonMLHoagwoodK. Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry2005; 44: 548–556.
8.
EfronDHiscockHSewellJR. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics2003; 111: 372–375.
9.
Cheng-ShannonJMcGoughJJPatakiCMcCrackenJT. Second-generation antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology2004; 14: 372–394.
10.
FindlingRLMcNamaraNK. Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. Journal of Clinical Psychiatry2004; 65: 30–44.
11.
JensenPSBuitelaarJPandinaGJBinderCHaasM. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. European Child and Adolescent Psychiatry2007; 16: 104–120.
12.
FindlingRLSteinerHWellerEB. Use of antipsychotics in children and adolescents. Journal of Clinical Psychiatry2005; 66(Suppl. 7)29–40.
13.
McConvilleBJSorterMTMcConvilleBJSorterMT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. Journal of Clinical Psychiatry2004; 65(Suppl. 6)20–29.
14.
PatelNCCrismonMHoagwoodKJensenPS. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. Journal of Child and Adolescent Psychopharmacology2005; 15: 270–284.
15.
ConnorDFFletcherKEWoodJS. Neuroleptic-related dyskinesias in children and adolescents. Journal of Clinical Psychiatry2001; 62: 967–974.
16.
CorrellCULeuchtSKaneJM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry2004; 161: 414–425.
17.
CorrellCUKaneJM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: A systematic review. Journal of Child and Adolescent Psychopharmacology2007; 17: 647–655.
18.
CorrellCUCarlsonHE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry2006; 45: 771–791.
19.
CorrellCUPenznerJBParikhUH. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America2006; 15: 177–206.
20.
KapetanovicSSimpsonGM. Review of antipsychotics in children and adolescents. Expert Opinion on Pharmacotherapy2006; 7: 1871–1885.
21.
TorenPRatnerSLaorNWeizmanA. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety2004; 27: 1135–1156.
22.
FedorowiczVJFombonneE. Metabolic side effects of atypical antipsychotics in children: a literature review. Journal of Psychopharmacology2005; 19: 533–550.
23.
BrydenKECarreyNJKutcherSP. Update and recommendations for the use of antipsychotics in early-onset psychoses. Journal of Child and Adolescent Psychopharmacology2001; 11: 113–130.
24.
CorrellCU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child and Adolescent Psychiatry.2007; 46: 687–700.
25.
GraciousBLFindlingRL. Antipsychotic medications for children and adolescents. Pediatric Annals2001; 30: 138–145.
26.
StiglerKAPotenzaMNPoseyDJMcDougleCJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatric Drugs2004; 6: 33–44.
27.
MasiGMucciMPariC. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs2006; 20: 841–866.
28.
StiglerKAPotenzaMNMcDougleCJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatric Drugs2001; 3: 927–942.
29.
CorrellCU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry2008; 47: 9–20.
30.
SaferDJ. A comparison of risperidone-induced weight gain across the age span. Journal of Clinical Psychopharmacology2004; 24: 429–436.
31.
FleischhakerCHeiserPHennighausenK. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission2007; 114: 273–280.
32.
RatzoniGGothelfDBrand-GothelfA. Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry2002; 41: 337–343.
33.
GentileS. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety2006; 29: 303–319.
34.
EbbelingCBPawlakDBLudwigDS. Childhood obesity: public-health crisis, common sense cure. The Lancet2002; 360: 473–482.
35.
HongYJinXMoJ. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality – results of prospective analysis for the Atherosclerosis Risk in Communities study. Journal of Internal Medicine2007; 262: 113–122.
36.
MartinAL'EcuyerS. Triglyceride, cholesterol and weight changes among risperidone-treated youths: a retrospective study. European Child and Adolescent Psychiatry2002; 11: 129–133.
37.
PatelNCHariparsadMMatias-AktharM. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology2007; 17: 303–311.
38.
TohenMKryzhanovskayaLCarlsonG. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. The American Journal of Psychiatry2007; 164: 1547–1556.
39.
GuoJJKeckPEJrCorey-LislePK. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry2006; 67: 1055–1061.
40.
KollerEACrossJTDoraiswamyPMSchneiderBS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy2003; 23: 735–744.
41.
GuoJJKeckPEJrCorey-LislePK. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy2007; 27: 27–35.
42.
KollerEACrossJTSchneiderB. Risperidone-associated diabetes mellitus in children. Pediatrics2004; 113: 421–422.
43.
BottaiTQuintinPPerrinE. Antipsychotics and the risk of diabetes: a general data review. European Psychiatry2005; 20: S349–S357.
44.
Harrison-WoolrychMGarcia-QuirogaJAshtonJHerbisonP. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Safety2007; 30: 569–579.
45.
LaitaPCifuentesADollA. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. Journal of Child and Adolescent Psychopharmacology2007; 17: 487–501.
46.
PappagalloMSilvaR. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. Journal of Child & Adolescent Psychopharmacology2004; 14: 359–371.
47.
SaitoECorrellCUGallelliK. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. Journal of Child and Adolescent Psychopharmacology2004; 14: 350–358.
48.
StallerJ. The effect of long-term antipsychotic treatment on prolactin. Journal of Child and Adolescent Psychopharmacology2006; 16: 317–326.
49.
AndersonGMScahillLMcCrackenJT. Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biological Psychiatry2007; 61: 545–550.
50.
BeckerALEppersonCNBeckerALEppersonCN. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Child and Adolescent Psychiatric Clinics of North America2006; 15: 207–220.
51.
WudarskyMNicolsonRHamburgerSD. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology1999; 9: 239–245.
52.
AlfaroCLWudarskyMNicolsonR. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of Child and Adolescent Psychopharmacology2002; 12: 83–91.
53.
DunbarFKusumakarVDanemanDSchulzM. Growth and sexual maturation during long-term treatment with risperidone. American Journal of Psychiatry2004; 161: 918–920.
54.
BlairJScahillLStateMMartinA. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study [see comment]. Journal of the American Academy of Child and Adolescent Psychiatry2005; 44: 73–79.
55.
LambertTJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. Journal of Clinical Psychiatry2007; 68(Suppl. 6)10–13.
56.
Gonzalez-HeydrichJRachesDWilensTELeichtnerAMezzacappaE. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. Journal of the American Academy of Child and Adolescent Psychiatry2003; 42: 1227–1233.
57.
PappadopulosEJensenPSSchurSB. Real world” atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophrenia Bulletin2002; 28: 111–121.
58.
NewcomerJWNasrallahHALoebelAD. The atypical antipsychotic therapy and metabolic issues national survey. Journal of Clinical Psychopharmacology2004; 24(Suppl. 1)S1–S6.
59.
BuckleyPFMillerDDSingerBArenaJStirewaltEM. Clinicians’ recognition of the metabolic adverse events of antipsychotic medications. Schizophrenia Bulletin2005; 79: 281–288.
60.
KetterTAHauptDW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Current Medical Research and Opinion2006; 22: 2345–2353.
61.
DoeyTHandelmanKSeabrookJASteeleM. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Canadian Journal of Psychiatry2007; 52: 363–368.
62.
ClarkNC. Consensus development conference on antipsychotic drugs and obsesity and diabetes. Diabetes Care2004; 27: 596–601.
63.
ViewegWVSoodABPandurangiASilvermanJJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?. Acta Psychiatrica Scandinavica2005; 111: 177–184.
64.
CorrellCU.Monitoring and management of antipsychotic-related metabolic and endocrine adverse effects in children and adolescents. International Review of Psychiatry(in press).
65.
NasrallahHANewcomerJW. Atypical antipsychotics and metabolic dysregulation. Evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology2004; 24(Suppl. 1)S7–S14.
66.
CorrellCU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectrums2007; 12(Suppl. 17)12–20.
